EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases

Rupert W Leong iD, Anthony Sakiris iD, Arteen Arzivian iD, John David Chetwood iD, Thanaboon Chaemsupaphan iD, Miles P Sparrow iD, Michael A Kamm iD, Viraj Kariayawasam iD, Australian IBD Consensus Working Group

Alimentary Pharmacology & Therapeutics · 2025-01 · 61 (1) · 132-144

DOI: 10.1111/apt.18318 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-10-10. Written by Rupert W Leong and 8 co-authors. Institution: Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia. Major MEDLINE topics: Inflammatory Bowel Diseases, Vaccination, Delphi Technique. Cited 11 times so far (Crossref); 107 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Given the introduction of new advanced therapies for inflammatory bowel diseases (IBDs), expanded risk mitigation strategies are essential.

Aims

To create a comprehensive set of statements on assessment procedures and vaccinations before starting monoclonal antibodies, Janus kinase (JAK) inhibitors or sphingosine‐1‐phosphate (S1P) modulators for IBD.

Methods

We examined literature, guidelines and drug product information regarding vaccination and assessment recommendations for initiating advanced IBD therapies. Using a modified Delphi approach, delegates voted anonymously on the acceptability of these statements prior to and following consensus discussion.

Results

We developed eight statements on the domains of infectious diseases screening, vaccinations and assessments prior to commencing JAK inhibitors and S1P modulators. Six statements received agreement. Pre‐advanced therapy screening for infectious diseases was established, and the vaccination protocol was revised. Malignancy, cardiovascular and thromboembolic risk assessments are necessary before initiating JAK inhibitors. Those starting S1P modulators need cardiac and ophthalmic assessments.

Conclusions

These consensus statements combine vaccination and assessments on the currently available advanced therapies for IBD as a single comprehensive document that may reduce IBD complications associated with use of advanced therapies. Knowledge gaps identified during the consensus process will provide further research opportunities.

Subjects

MeSH terms (MEDLINE)

Inflammatory Bowel DiseasesVaccinationDelphi TechniqueHumansJanus Kinase InhibitorsAntibodies, MonoclonalSphingosine 1 Phosphate Receptor Modulators

Author keywords

Crohn's diseaseadvanced therapyadverse eventinfectioninflammatory bowel diseasescreeningthromboembolismulcerative colitisvaccination

Substances

Janus Kinase InhibitorsAntibodies, MonoclonalSphingosine 1 Phosphate Receptor Modulators

Authors and institutions

  • Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Gastroenterology and Hepatology, Westmead Hospital, Sydney, New South Wales, Australia.
  • Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Department of Gastroenterology, School of Translational Medicine, Monash University and Alfred Health, Melbourne, Victoria, Australia.

ORCID profiles: Rupert W Leong, Anthony Sakiris, Arteen Arzivian, John David Chetwood, Thanaboon Chaemsupaphan, Miles P Sparrow, Michael A Kamm, Viraj Kariayawasam

Cite

APA

Leong, R. W., Sakiris, A., Arzivian, A., Chetwood, J. D., Chaemsupaphan, T., Sparrow, M. P., Kamm, M. A., Kariayawasam, V., & Australian IBD Consensus Working Group (2025). Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases. Alimentary Pharmacology & Therapeutics, 61(1), 132-144. https://doi.org/10.1111/apt.18318

Vancouver

Leong RW, Sakiris A, Arzivian A, Chetwood JD, Chaemsupaphan T, Sparrow MP, et al. Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases. Alimentary Pharmacology & Therapeutics. 2025;61(1):132-144. doi:10.1111/apt.18318

BibTeX
@article{Leong2025,
  author = {Leong, Rupert W and Sakiris, Anthony and Arzivian, Arteen and Chetwood, John David and Chaemsupaphan, Thanaboon and Sparrow, Miles P and Kamm, Michael A and Kariayawasam, Viraj and Australian IBD Consensus Working Group, Australian IBD Consensus Working Group},
  title = {Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  volume = {61},
  number = {1},
  pages = {132--144},
  doi = {10.1111/apt.18318}
}
Start for free →